Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

Summary

The purpose of this study is to evaluate the efficacy and safety of ethyl icosapentate in Chinese patients with severe hypertriglyceridemia.

Timeline

Start

2020-05-09

Primary completion

2023-07-20

Completion

2023-07-20

Outcome

Met primary endpoint

paper The MND-21 3600 mg group exhibited a significantly greater reduction in TG levels compared with the placebo group (P = .049). PMID 41500861 ↗

Publications

• Wang Y, Long M, Chen F, Wu D, Pei Z, Wang X, Zhao W, Mori T, Zhao S. Efficacy and safety of highly purified ethyl icosapentate soft capsules (MND-21) for the treatment of severe hypertriglyceridemia: A 12-week, multi-center, placebo-controlled, randomized, double-blind, phase III clinical trial in China. J Clin Lipidol. 2026 Feb;20(2):289-298. doi: 10.1016/j.jacl.2025.12.007. Epub 2025 Dec 14.

Drugs

Indications